BioSpace News Archive

Neuronetics, Inc. announced it has amended its term loan agreement with its current lenders, investment affiliates managed by SLR Investment Corp., which was originally entered into on March 2, 2020 and subsequently amended on April 20, 2020 and December 2, 2020.

Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (“Renalytix” or the “Company”) today announced the Company will be presenting at the upcoming virtual Cowen 42nd Annual Health Care Conference.

Otonomy, Inc. today announced the completion of patient enrollment in the Phase 2 clinical trial of OTO-313 in tinnitus.

Gracell Biotechnologies Inc. today announced multiple advancements of its TruUCAR platform, the Company’s proprietary technology platform designed to generate high-quality allogeneic CAR-T cell therapies that can be administered “off-the-shelf” as stand-alone therapy at lower cost and with greater convenience.

Stealth BioTherapeutics Corp today announced that Reenie McCarthy , CEO, will present at the virtual Mitochondria-Targeted Drug Development Summit on Thursday, February 24, 2022 at 9:00 a.m. ET.

Biohaven Pharmaceutical Holding Company Ltd. today announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec® ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.

Provention Bio, Inc. today announced it has resubmitted the Biologics License Application (BLA) for teplizumab for the delay of clinical type 1 diabetes (T1D) in at-risk individuals.

Mitsubishi Corporation Life Sciences Limited (Head Office: Chiyoda-ku, Tokyo Japan; Hiroshi Fujiki, representative director and president) announces that the U.S. Patent and Trademark Office has granted a patent, US 11,207,371 B21, to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient.

Statera Biopharma, Inc. today announced unaudited, preliminary revenue and other financial results for its Fiscal Year ended December 31, 2021.

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Monday, March 14th, 2022.